Ferd has acquires a 33 per cent share in Aidian, a Finnish developer, manufacturer and vendor of instruments and tests that are used in such fields as primary care to provide quick and accurate test results.
Ardian was acquired by Swedish family-controlled investment firm Nordstjernan earlier this year.
Aidian’s range of tests addresses several global health problems, such as antimicrobial resistance (AMR), diabetes and colorectal cancer. Aidian has tests that are intended to reduce unnecessary prescriptions of antibiotics, which is a driver behind the growing threat from AMR and antibiotic-resistant bacteria.
The parties have agreed not to disclose the terms of the transaction.
